Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

Rudd proposes that GP’s take on care of diabetics

In a bid to ease the strain caused by diabetes on the hospitals, Australian Prime Minister, Kevin Rudd has proposed that GP’s take on care of diabetics. For every diabetes patient that a GP handles, the government will pay the doctor $1200 a year to cover day-to-day costs. Each GP will receive up to $10,800 annually based on performance.

1 Apr 2010

Worker health checks reveal 50% men at risk of developing diabetes

Over the last one year 100,000 State Government financed worker health check ups have been conducted. The results have been an eye-opener. 800 workers after their check ups have been asked to consult their physicians immediately. These check ups included measurements of blood pressure, blood cholesterol, blood sugar and waist circumference. The workers were also questioned regarding their eating, drinking and exercising habits.

1 Apr 2010

Breastfeeding benefits expanded to cover mothers: Risk of diabetes reduced

Research has found a new benefit that mothers can obtain by breast feeding – decreased risk of type 2 diabetes. Benefits of breastfeeding for the baby have been cited for a long time now. In spite of this knowledge according to The Australian Breastfeeding Association there is a definite gap in awareness regarding health benefits that this simple yet effective practice can offer.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

VIVUS terminates Luramist development, commercialization agreement with FemPharm

VIVUS, Inc. today announced that it has terminated the Development and Commercialization Agreement with FemPharm Pty Ltd. (a wholly owned subsidiary of Acrux Limited) for Luramist™, a metered dose transdermal application of testosterone for women.

1 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

Personalized online resource to help Canadians achieve healthy weight loss

A Heart and Stroke Foundation survey of almost 2,000 Canadians found that 62% reported intentionally losing five or more pounds over the past five years but failed to keep the weight off. And 70% of those who were overweight or obese regained all or even more pounds after their weight-loss efforts.

1 Apr 2010

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

A Kansas State University researcher is exploring the use of Chinese wolfberries to improve vision deficiencies that are common for type-2 diabetics.

31 Mar 2010

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

The Fairbanks Institute for Healthy Communities, the Indianapolis not-for-profit organization working to improve community health, and BioServe, a global provider of biomaterial and genetic research services, today announced that they will co-market INbank™, a next generation biorepository that was recently launched by The Fairbanks Institute.

31 Mar 2010

Drinking orange juice with fast-food meal may help prevent vascular inflammation

Eating foods containing flavonoids -- orange juice, in this case -- along with a high-fat, high-carbohydrate fast-food meal neutralizes the oxidative and inflammatory stress generated by the unhealthy food and helps prevent blood vessel damage, a new study by University at Buffalo endocrinologists shows.

31 Mar 2010

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

31 Mar 2010

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

31 Mar 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

GSK re-submits sNDA for Avodart to FDA

GlaxoSmithKline announced today that it has re-submitted the supplemental New Drug Application for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration.

30 Mar 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.

30 Mar 2010

Conference on the actions of Vitamin D on human health

An important conference on the actions of Vitamin D on human health is being hosted by Barts and The London Medical School and the MRC Asthma UK Centre in Allergic Mechanisms of Asthma.

30 Mar 2010

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

People with diabetes who undergo cancer surgery have greater risk of death: Study

People with diabetes who undergo cancer surgery are more likely to die in the month following their operations than those who have cancer but not diabetes, an analysis by Johns Hopkins researchers suggests.

29 Mar 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Rudd proposes that GP’s take on care of diabetics

Worker health checks reveal 50% men at risk of developing diabetes

Breastfeeding benefits expanded to cover mothers: Risk of diabetes reduced

New medicines to fight diseases of particular concern to African Americans

VIVUS terminates Luramist development, commercialization agreement with FemPharm

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Personalized online resource to help Canadians achieve healthy weight loss

Researcher explores the use of Chinese wolfberries to improve vision deficiencies

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

Drinking orange juice with fast-food meal may help prevent vascular inflammation

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

Depomed licensee submits DM-1796 NDA for management of PHN

Patients switching to Victoza experience further reductions in A1c and weight loss

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

GSK re-submits sNDA for Avodart to FDA

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Conference on the actions of Vitamin D on human health

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

People with diabetes who undergo cancer surgery have greater risk of death: Study

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in